But NACs antioxidant activity has raised questions about how it might behave in people who already have cancer or cancer-prone cells
Diabetes Obes Metab 19:14361445 Tillner J, Posch MG, Wagner F et al (2019) A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials
Moreover, the lower dose of Orfoglipron that has previously been tested in ATTAIN-1 (12mg) was not used as a long-term maintenance dose in this study
16,17,18,19 As new indications continue to be developed, GLP-1 drugs demonstrate immense potential in the medical field, with future research expected to expand their therapeutic applications
V.NguyenS
China Patent Application CN105238797 (A) Ye C, Liu Y, Wang Y, Li H, Wang K (2016) Glutathione beautifying yogurt and production method thereof